Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.80%14.95B | 7.41%3.7B | 12.64%4.15B | 72.04%14.54B | 92.05%3.86B | 77.44%3.55B | 64.83%3.44B | 56.74%3.69B | 13.67%8.45B | 3.96%2.01B |
Cost of revenue | 5.24%8.08B | 10.53%2B | 22.43%2.2B | 124.50%7.67B | 167.36%2.11B | 108.39%1.96B | 123.35%1.81B | 104.35%1.8B | 32.45%3.42B | 9.93%789.25M |
Gross profit | 0.07%6.87B | 3.97%1.7B | 3.33%1.95B | 36.41%6.87B | 43.31%1.75B | 50.03%1.59B | 27.90%1.64B | 28.28%1.89B | 3.69%5.03B | 0.44%1.22B |
Operating expense | -2.90%5.58B | -1.82%1.36B | 2.40%1.45B | 44.75%5.75B | 36.62%1.45B | 45.42%1.49B | 44.12%1.39B | 54.04%1.42B | 29.29%3.97B | 31.93%1.06B |
Operating profit | 15.31%1.29B | 36.18%339.97M | 6.14%496.03M | 5.29%1.12B | 88.80%295.12M | 166.14%107.91M | -21.33%249.64M | -14.96%467.33M | -40.37%1.06B | -61.72%156.31M |
Net non-operating interest income (expenses) | -5.23%-13.83M | 7.98%-3.06M | 9.55%-3.1M | -1,420.72%-13.14M | -1,051.87%-3.09M | -1,181.40%-3.31M | -2,085.53%-3.32M | -1,740.86%-3.42M | 47.70%-864K | -0.37%-268K |
Non-operating interest income | 201.06%569K | -59.38%26K | -20.00%28K | -15.25%189K | -15.94%58K | -20.00%32K | -8.57%64K | -20.45%35K | -8.23%223K | -4.17%69K |
Non-operating interest expense | 8.01%14.4M | -8.95%3.08M | -9.66%3.13M | 1,126.13%13.33M | 833.23%3.15M | 1,020.13%3.34M | 1,425.23%3.39M | 1,403.91%3.46M | -42.64%1.09M | -0.59%337K |
Net investment income | 0 | -182K | -2,140.00%-112K | |||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -117.65M | ||||||||
Income from associates and other participating interests | -4.17%55.16M | -1.37%13.22M | 13.89%14.59M | 25.00%57.56M | 63.38%15.93M | 13.25%15.42M | 10.20%13.41M | 21.75%12.81M | 34.56%46.05M | 18.72%9.75M |
Special income (charges) | 21,373.48%1.06B | -8,504.00%-286.43M | -1,470.37%-848K | -585.16%-4.99M | 52.03%-296K | -4,413.79%-1.31M | -19,482.35%-3.33M | 16.92%-54K | 92.56%-728K | 22.39%-617K |
Less:Restructuring and mergern&acquisition | --35.03M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Other special charges | -27,719.63%-1.38B | 47.43%4.91M | 1,470.37%848K | 585.16%4.99M | -52.03%296K | 4,413.79%1.31M | 19,482.35%3.33M | -16.92%54K | -30.20%728K | -37.36%617K |
Less:Write off | --281.52M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | -565.04%-22.42M | -98.72%55K | -950.86%-20.68M | -13.76%4.82M | -52.30%2.43M | 125.65%69K | 727.61%4.29M | -916.60%-1.97M | 4.98%5.59M | 783.71%5.1M |
Income before tax | 126.59%2.37B | -75.52%63.76M | 2.40%485.99M | -6.03%1.05B | 13.19%192.74M | 121.60%118.78M | -21.02%260.5M | -15.26%474.58M | -38.53%1.11B | -59.08%170.28M |
Income tax | 113.59%871.92M | 4.81%144.01M | -7.12%192.29M | 36.51%408.23M | -552.81%-31.38M | 380.13%95.17M | 43.59%137.4M | 17.24%207.04M | -37.67%299.04M | -86.87%6.93M |
Net income | 134.91%1.5B | -165.19%-80.25M | 9.78%293.7M | -21.65%638.38M | 37.21%224.13M | -30.12%23.61M | -47.43%123.1M | -30.22%267.55M | -38.85%814.73M | -55.04%163.35M |
Net income continuous operations | 134.90%1.5B | -165.19%-80.25M | 9.78%293.7M | -21.64%638.38M | 37.21%224.13M | -30.11%23.61M | -47.43%123.1M | -30.22%267.55M | -38.85%814.73M | -55.04%163.35M |
Noncontrolling interests | -13.91%17.82M | -21.99%10.17M | 243.13%4.01M | 784.99%20.7M | 172.39%15.11M | 79.08%-4.64M | 113.92%13.03M | -121.74%-2.8M | -93.97%2.34M | -57.60%5.55M |
Net income attributable to the company | 139.89%1.48B | -182.15%-90.41M | 7.15%289.69M | -23.97%617.68M | 32.46%209.02M | -49.53%28.25M | -51.74%110.06M | -27.04%270.35M | -37.19%812.39M | -54.94%157.8M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 139.89%1.48B | -182.15%-90.41M | 7.15%289.69M | -23.97%617.68M | 32.46%209.02M | -49.53%28.25M | -51.74%110.06M | -27.04%270.35M | -37.19%812.39M | -54.94%157.8M |
Gross dividend payment | ||||||||||
Basic earnings per share | 140.95%68.26 | -183.60%-4.18 | 7.57%13.36 | -24.69%28.33 | 31.96%9.62 | -50.19%1.29 | -52.65%5 | -27.71%12.42 | -37.37%37.62 | -55.14%7.29 |
Diluted earnings per share | 143.87%68.26 | -184.10%-4.18 | 10.60%13.36 | -21.77%27.99 | 37.04%9.62 | -50.80%1.23 | -50.45%4.97 | -25.57%12.08 | -36.39%35.78 | -53.60%7.02 |
Dividend per share | 0.00%4.5 | 0 | 0 | 4.5 | 4.5 | |||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |